Press Release: Basilea enters into sale and leaseback agreement for corporate headquarters building

Basel, Switzerland, June 23, 2020

Basilea Pharmaceutica Ltd. (SIX: BSLN) today announced that it has

entered into a sale and leaseback agreement for its corporate

headquarters in Basel, with the Pension Fund of UBS. Gross proceeds from

the sale, before customary fees and transaction costs, amount to around

CHF 19 million. Basilea will leaseback the building and does not plan on

any other organizational changes related to this transaction. CBRE

(NYSE: CBRE) represented Basilea as sell-side advisors.

David Veitch, Chief Executive Officer of Basilea, said: "This

transaction is an important strategic step for Basilea and a result of

our continuous efforts to optimize our business. It significantly

increases our financial and operational flexibility, and allows us to

move forward with our mid-term plan of bringing all our employees,

currently working at different locations across Basel, together at a new

location in the area. The transaction allows us to further focus on our

core business; the discovery, development and commercialization of

treatments for patients with cancer or with fungal and bacterial

infections."

About Basilea

Basilea Pharmaceutica Ltd. is a commercial-stage biopharmaceutical

company, focused on the development of products that address the medical

challenges in the therapeutic areas of oncology and infectious diseases.

With two commercialized drugs, the company is committed to discovering,

developing and commercializing innovative pharmaceutical products to

meet the medical needs of patients with serious and life-threatening

conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel,

Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional

information can be found at Basilea's website

https://www.globenewswire.com/Tracker?data=0cx1nH7OBX26MIz9UZdhMPuJA6OenYVigjHD7YLUFm5FATVYhivDRfqIeSyDDxBN_D94UY9JnQwEiYjfYxqjEA==

www.basilea.com.

Disclaimer

This communication expressly or implicitly contains certain

forward-looking statements, such as "believe", "assume", "expect",

"forecast", "project", "may", "could", "might", "will" or similar

expressions concerning Basilea Pharmaceutica Ltd. and its business,

including with respect to the progress, timing and completion of

research, development and clinical studies for product candidates. Such

statements involve certain known and unknown risks, uncertainties and

other factors, which could cause the actual results, financial condition,

performance or achievements of Basilea Pharmaceutica Ltd. to be

materially different from any future results, performance or

achievements expressed or implied by such forward-looking statements.

Basilea Pharmaceutica Ltd. is providing this communication as of this

date and does not undertake to update any forward-looking statements

contained herein as a result of new information, future events or

otherwise.

For further information, please contact:

Peer Nils Schröder, PhD

Head of Corporate Communications & Investor Relations

Phone +41 61 606 1102

E-mail mailto:media_relations@basilea.com media_relations@basilea.com

mailto:investor_relations@basilea.com investor_relations@basilea.com

-----------------------------------------------------------------------

This press release can be downloaded from

https://www.globenewswire.com/Tracker?data=0cx1nH7OBX26MIz9UZdhMJ56gUgWPQ5puDpEc3yzfPQC7qbHUQejRcP5NfLn4zlYW52SNOiewCQL41vZhykL9g==

www.basilea.com.

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/73f3c6ca-5ca9-4515-8198-702b70316116

(END) Dow Jones Newswires

June 23, 2020 13:00 ET (17:00 GMT)